Tonix Reports Positive Phase 3 RESILIENT Data for TONMYA in Fibromyalgia Patients

Tonix Pharmaceuticals presented positive results from its Phase 3 RESILIENT study of TONMYA for fibromyalgia at the 2026 Non-Opioid Pain Therapeutics Summit. The study showed that patients treated with sublingual TONMYA experienced significant reductions in weekly average pain scores, along with improvements in sleep disturbance and fatigue. TONMYA was well tolerated and had minimal impact on weight and blood pressure. The FDA approved TONMYA in August 2025 for the treatment of fibromyalgia in adults.